We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
By Dave Sebastian
Merck & Co. Inc. said it raised its adjusted-earnings outlook and narrowed its revenue guidance for the full year, as it continues to see strength in its underlying business, but it lowered its earnings guidance as the company expects the pandemic to weigh on some of its results.
The company said it expects adjusted earnings of $5.91 a share to $6.01 a share on revenue of $47.6 billion to $48.6 billion. It previously guided for adjusted earnings of $5.63 a share to $5.78 a share on revenue of $47.2 billion to $48.7 billion.
Merck said it expects earnings of $4.55 a share to $4.65 a share, compared with its prior outlook of $5.63 a share to $5.78 a share. It expects operating expenses to be higher than the prior year by a low-single-digit rate.
Merck said it expects the pandemic to hurt revenue by about $2.35 billion, excluding foreign exchange. That would comprise about $2.3 billion for pharmaceuticals and about $50 million for animal health.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 27, 2020 07:37 ET (11:37 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions